GLPGGalapagos
About Galapagos
Galapagos (AMS:GLPG) (NASDAQ:GLPG) is a dynamic biotechnology firm focused on the discovery and development of small molecule medicines with novel modes of action. Its portfolio boasts a wide range of projects targeting various diseases, with a strong emphasis on immunology, inflammation, and fibrosis. Galapagos aims to improve patient health by pushing the boundaries of medical research and bringing innovative treatments to the market. The company's commitment to rigorous scientific research, collaborative partnerships, and patient-centric development strategies underline its mission to develop first-in-class and best-in-class therapeutics. Through its efforts, Galapagos is dedicated to making a significant impact on the lives of patients worldwide.
What is GLPG known for?
Snapshot
Public US
Ownership
1999
Year founded
1150
Employees
Mechelen, Belgium
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Kingdom of Belgium
Produtos e/ou serviços de Galapagos
- Drug Discovery and Development: Their core activity is identifying promising drug candidates through scientific research and preclinical testing.
- Clinical Trials: They conduct clinical trials in humans to evaluate the safety and efficacy of their drug candidates in various stages of development.
- Regulatory Affairs: They work with regulatory agencies like the FDA to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
- Partnerships and Collaborations: Galapagos may collaborate with other pharmaceutical companies to leverage expertise and resources for broader development and commercialization of their drugs.
- Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they partner with other companies to ensure the quality and supply of their drugs if they reach the market.
- Commercialization: Once approved, they work with healthcare providers and patient advocacy groups to raise awareness and ensure access to their medications.
equipe executiva do Galapagos
- Mr. Henry GosebruchCEO & Executive Director
- Mr. Aaron L. CoxChief Financial Officer
- Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
- Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
- Marieke VermeerschHead of Corporate Communication
- Ms. Annelies MissottenExecutive VP & Chief Human Resources Officer
- Ms. Ellen Van Der AarHead of Development
- Mr. Patrik RingblomHead of Strategy & US Lead
- Dr. Jeevan ShettyHead of Clinical Development Oncology
- Ruiz AstigarragaHead of Manufacturing Cell Therapy